ConductScience.org, home

Paper25904367

Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.

Sterling TR and 9 others. Clin Infect Dis, 2015. Cited by 86 papers, by iCite.

Cite this record

ConductScience Library. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Papers, record 25904367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25904367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2015
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
86
iCite
Relative citation ratio, by iCite
3.47
iCite
Revised in PubMed
2026-05-18
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sterling TRTimothy R
2Moro RNRuth N
3Borisov ASAndrey S
4Phillips EElizabeth
5Shepherd GGillian
6Adkinson NFNewton Franklin
7Weis SStephen
8Ho CChristine
9Villarino MEMargarita Elsa
10Tuberculosis Trials ConsortiumGroup

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
IsoniazidMajor topic
Latent TuberculosisMajor topic
Respiratory Tract DiseasesMajor topic
RifampinMajor topic
Adolescent
Adult
Female
Humans
Male
Middle Aged
Prospective Studies

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 AI094189NIAID NIH HHSUnited StatesP30AI094189PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00023452Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis InfectionDerived from the trialYesClinicalTrials.gov
NCT01582711Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOTBackgroundClinicalTrials.gov
NCT02980016Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive IndividualsBackgroundClinicalTrials.gov
NCT03783728Video Based Directly Observed Therapy for Latent TBResultsClinicalTrials.gov

Download CSV of trials

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12781610Severe 'flu'-like symptoms due to isoniazid--a report of three cases.Tubercle1989https://conductscience.org/library/papers/2781610PubMed
2637437Isoniazid and reaction to cheese.Ann Intern Med1978https://conductscience.org/library/papers/637437PubMed
37249508A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7249508PubMed
4578277Spiking fever from isoniazid simulating a septic process.JAMA1977https://conductscience.org/library/papers/578277PubMed
54620295Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects.Tubercle1974https://conductscience.org/library/papers/4620295PubMed
617448577Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Vaccine2007https://conductscience.org/library/papers/17448577PubMed
74544603
Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies.
Scand J Respir Dis Suppl1973https://conductscience.org/library/papers/4544603PubMed
84259217Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.Br Med J1972https://conductscience.org/library/papers/4259217PubMed
94468024Systemic reactions to intermittent rifampicin.Bull Int Union Tuberc1974https://conductscience.org/library/papers/4468024PubMed
1023592889Testing for drug hypersensitivity syndromes.Clin Biochem Rev2013https://conductscience.org/library/papers/23592889PubMed
113204279'Flu' syndrome on once monthly rifampicin.Indian J Lepr1988https://conductscience.org/library/papers/3204279PubMed
1223661919Isoniazid-induced flu-like syndrome: A rare side effect.Lung India2013https://conductscience.org/library/papers/23661919PubMed
1312241657Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.Lancet2002https://conductscience.org/library/papers/12241657PubMed
146614636Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis.Am Rev Respir Dis1983https://conductscience.org/library/papers/6614636PubMed
1525337749High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.N Engl J Med2014https://conductscience.org/library/papers/25337749PubMed
163784760A possible 'flu' syndrome on once-monthly rifampicin.Lepr Rev1986https://conductscience.org/library/papers/3784760PubMed
171096388
A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland.
Tubercle1975https://conductscience.org/library/papers/1096388PubMed
18766339The influence of age and sex on the incidence of the 'flu' syndrome and rifampicin-dependent antibodies in patients on intermittent rifampicin for tuberculosis.Tubercle1975https://conductscience.org/library/papers/766339PubMed
197730725"Flu" syndrome due to rifampin; experience with four cases.Int J Lepr Other Mycobact Dis1995https://conductscience.org/library/papers/7730725PubMed
201308530Rifampicin induced flu-syndrome and toxic psychosis.Indian J Lepr1992https://conductscience.org/library/papers/1308530PubMed

See all 38 referencesDownload CSV of references

Cited by53

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.

PMIDTitleJournalYearIn PapersSource
42237122Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis.BMC Infect Dis2026https://conductscience.org/library/papers/42237122PubMed
42136397Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.Clin Infect Dis2026https://conductscience.org/library/papers/42136397PubMed
41333648A Case of Evolving Hepatotoxicity Following Systemic Drug Reaction to Isoniazid-Rifapentine (3HP).Case Reports Hepatol2025https://conductscience.org/library/papers/41333648PubMed
40326358Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).Emerg Microbes Infect2025https://conductscience.org/library/papers/40326358PubMed
40262275Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden.Emerg Microbes Infect2025https://conductscience.org/library/papers/40262275PubMed
39957776The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.Lancet Reg Health Southeast Asia2024https://conductscience.org/library/papers/39957776PubMed
39887565Tuberculosis: An Update for the Clinician.Respirology2025https://conductscience.org/library/papers/39887565PubMed
39733063Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review.Drugs2025https://conductscience.org/library/papers/39733063PubMed
39582503Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda.Open Forum Infect Dis2024https://conductscience.org/library/papers/39582503PubMed
39374926Diagnosis and Treatment of Latent Tuberculosis Infection in Adults in South Korea.Tuberc Respir Dis (Seoul)2025https://conductscience.org/library/papers/39374926PubMed
39301134Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.IJTLD Open2024https://conductscience.org/library/papers/39301134PubMed
38640958Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.J Infect Dis2024https://conductscience.org/library/papers/38640958PubMed
37931950Syndrome pseudogrippal avec choc induit par la rifampicine chez une patiente atteinte d’infection tuberculeuse.CMAJ2023https://conductscience.org/library/papers/37931950PubMed
37918510Tuberculosis prevention: current strategies and future directions.Clin Microbiol Infect2024https://conductscience.org/library/papers/37918510PubMed
37855280An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions.Med Chem2024https://conductscience.org/library/papers/37855280PubMed
37669793Rifampin-induced flu-like syndrome with shock in a patient with tuberculosis infection.CMAJ2023https://conductscience.org/library/papers/37669793PubMed
37339341Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.J Int AIDS Soc2023https://conductscience.org/library/papers/37339341PubMed
37143101Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials.Arch Public Health2023https://conductscience.org/library/papers/37143101PubMed
36966788Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.Lancet Respir Med2023https://conductscience.org/library/papers/36966788PubMed
36815322Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.Clin Infect Dis2023https://conductscience.org/library/papers/36815322PubMed

See all 53 cited byDownload CSV of cited by

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
PYRIDOXINECHEMBL1364Results1https://conductscience.org/library/drugs/CHEMBL1364ChEMBL
RIFAPENTINECHEMBL1660Results2https://conductscience.org/library/drugs/CHEMBL1660ChEMBL
ISONIAZIDCHEMBL64Results2https://conductscience.org/library/drugs/CHEMBL64ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25904367

GET https://conductscience.org/api/papers/v1/25904367/references?page=2